Medicus Pharma Statistics
Total Valuation
Medicus Pharma has a market cap or net worth of $42.76 million. The enterprise value is $42.63 million.
Important Dates
The last earnings date was Monday, August 11, 2025, after market close.
Earnings Date | Aug 11, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Medicus Pharma has 17.82 million shares outstanding. The number of shares has increased by 89.21% in one year.
Current Share Class | 17.82M |
Shares Outstanding | 17.82M |
Shares Change (YoY) | +89.21% |
Shares Change (QoQ) | +16.70% |
Owned by Insiders (%) | 20.79% |
Owned by Institutions (%) | 16.18% |
Float | 10.34M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 12.80 |
P/TBV Ratio | 14.53 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 1.57.
Current Ratio | 1.29 |
Quick Ratio | 1.13 |
Debt / Equity | 1.57 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -352.45% and return on invested capital (ROIC) is -140.66%.
Return on Equity (ROE) | -352.45% |
Return on Assets (ROA) | -102.95% |
Return on Invested Capital (ROIC) | -140.66% |
Return on Capital Employed (ROCE) | -503.24% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Dividends & Yields
Medicus Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -89.21% |
Shareholder Yield | -89.21% |
Earnings Yield | -36.21% |
FCF Yield | n/a |
Analyst Forecast
The average price target for Medicus Pharma is $23.50, which is 879.17% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $23.50 |
Price Target Difference | 879.17% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on October 25, 2024. It was a reverse split with a ratio of 1:2.
Last Split Date | Oct 25, 2024 |
Split Type | Reverse |
Split Ratio | 1:2 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |